Press Releases
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
GT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
